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ABSTRACT 
The new coronavirus (SARS-CoV-2), which caused the global pandemic Coronavirus Disease-2019 
(COVID-2019), has infected nearly 206 countries. There is still little information about molecular 
compounds that can inhibit the development of infections caused by this disease. It is crucial to discover 
competent natural inhibitor candidates, such as antiviral peptides, because they have a variety of biological 
activities and have evolved to target biochemical machinery from different pathogens or host cell structures. 
In silico studies will be carried out, including protein-peptide docking and protein-protein docking, to 
identify, evaluate, and explore the affinity and molecular interactions of the Magainin-1 and Magainin-2 
peptide molecules derived from frog skin (Xenopus laevis) to the main protease macromolecule (Mpro) 
SARS-CoV-2, and its effect on the ACE-2 receptor (Angiotensin Converting Enzyme-2 Receptor). Protein-
peptide docking simulations show that both peptide molecules have a good affinity for the active site area 
of the SARS-CoV-2 Mpro macromolecule. These results were then confirmed using protein-protein 
docking simulations to observe the ability of the peptide molecule in preventing attachment to the ACE-2 
receptor surface area. In silico studies show that Magainin-2 has the best affinity, with a bond free energy 
value of −3054.53 kJ/mol. Then the protein-protein docking simulation provided by Magainin-2 prevented 
the attachment of ACE-2 receptors, with an ACE score of 1697.99 kJ/mol. Thus, through in silico research, 
the Magainin peptide molecule can be further investigated in the development of new antiviral peptides for 
the treatment of infectious diseases of COVID-19. 
 
Keywords: antiviral peptide; COVID-19; in silico; Magainin; SARS-CoV-2 
 
INTRODUCTION 
The emergence of symptoms such as fever, 
cough, fatigue, sputum production, shortness of 
breath, sore throat, headache along with several 
reports of diarrhea and vomiting began to 
increase as a cause of pneumonia cases since 
December 2019 and later identified as a new 
coronavirus in Wuhan, Hubei Province, China 
(Guan et al., 2020; Wang et al., 2020). On 
January 12, 2020, the WHO first named the 
2019-novel coronavirus (2019-nCoV) and 
officially referred to this disease as the 
coronavirus 2019 (COVID-19) and as a global 
emergency disease as a result of concern 
globally. The International Committee of 
Coronavirus Study Group (CSG) recommends 
using the name as SARS-CoV-2, published on 
February 11, 2020 (Guo et al., 2020). 
Two overlapping polyproteins function to 
encode the SARS-CoV-2 genome consisting of 
~30,000 nucleotides, namely pp1a and pp1ab. 
Both polyproteins are needed by coronavirus 
for replication and transcription (Lu et al., 
2020). Through this polyprotein, a functional 
polypeptide is released through a proteolytic 
process involving the main protease (Mpro) of 
SARS-CoV-2 (Ge et al., 2013). Previous 
studies have shown that the functional structure 
between SARS-CoV-2 and SARS-CoV is 
identical based on the genome's complete 
phylogenetic analysis (Chen et al., 2009; Letko 
et al., 2020). By analyzing the order and 
analysis of the evolution of this coronavirus, it 
is suspected that bats act as coronavirus's 
natural hosts. The coronavirus may have been 
transferred to humans as an intermediate host 
by binding to the ACE-2 receptor (Angiotensin 
Converting Enzyme-2 Receptor) (Zhou et al., 
2020). 
ACE-2 receptors act as functional 
receptors because they can mediate 
coronaviruses' entry (SARS-CoV or SARS-
CoV-2) into host cells. SARS-CoV-2 involves 
the ACE-2 receptor's surface with an affinity 
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comparable to SARS-CoV (Kirchdoerfer et al., 
2018; Walls et al., 2019). A strong bond at the 
ACE-2 receptor can explain part of the efficient 
transmission of SARS-CoV-2 in humans, as 
occurs in SARS-CoV (Park et al., 2016). 
Therefore, the inhibition of the attachment of 
SARS-CoV-2 to the ACE-2 receptor is a 
pathway in developing natural inhibitors for 
infectious diseases of COVID-19. 
Some literature describes frog skin's 
antiviral activity (Xenopus laevis) because it is 
considered an abundant source of antiviral 
peptides. These peptides are produced in skin 
glands, are deployed in stressful events, and 
present cationic α-helical secondary structures, 
with 10-50 amino acids (Marcocci et al., 2018; 
Shartouny & Jacob, 2019). Magainin-1 and 
Magainin-2 are examples of antiviral peptides 
with 23 amino acid residues and show efficient 
inhibition of viruses (Matanic & Castilla, 
2004). Previously, several variants of Magainin 
also presented lysine-rich regions or many 
lysine residues in their structures, showing the 
best results in inhibiting viruses. Previous 
research has suggested that cationic loading 
associated with amphipathic structures can 
allow these peptides to interact with anionic 
phospholipids in viral envelopes, consequently 
disrupting their structure by several unknown 
mechanisms and exerting virucidal activity 
(Dean et al., 2010). 
Through this research, the mechanism of 
action of the antiviral peptides Magainin-1 and 
Magainin-2 will be proven against SARS-CoV-
2 Mpro and their effect on inhibiting the 
binding of ACE-2 receptors' binding using in 
silico. This in silico study can be utilized to 
identify, evaluate, and characterize potential 
components of SARS-COV-2 (Kumar et al., 
2020). In particular, SARS-CoV-2 Mpro has 
been considered a target because it is a major 
part of forming coronavirus characteristics. 
Thus, the results of this research are expected to 
obtain the structure of a reference antiviral 
peptide in developing a candidate drug for 
COVID-19 infection. 
 
MATERIALS AND METHODS 
SARS-CoV-2 Mpro Macromolecule 
Preparation. The macromolecules used are the 
main proteases (Mpro) of the novel coronavirus 
2019 (2019-nCoV or SARS-CoV-2) 
downloaded from Protein Data Bank 
(http://www.rcsb.org/pdb) with PDB ID 6LU7 
(Jin et al., 2020). SARS-CoV-2 Mpro 
macromolecules were prepared by removing 
water molecules and natural inhibitors, adding 
polar hydrogen atoms, and calculating the 
Kollman charge. 
Antiviral Peptide Molecule Preparation. 
The test molecule used was the sequencing of 
the antiviral peptide Magainin-1 and Magainin-
2 derived from the frog skin (Xenopus laevis), 
which had been modeled using PEPFOLD 3.5 
(http://bioserv.rpbs.univ-paris-diderot.fr/PEP-
FOLD/) (Figure 1). PEP-FOLD 3.5 is a server 
that is used to model peptide sequencing into 
three-dimensional conformation using the de 
novo method with amino acids between 5 and 
50 (Maupetit et al., 2009; Thévenet et al., 2012; 
Chavan & Deobagkar, 2015; Lamiable et al., 
2016). This method can obtain a peptide 
sequence without the protein database that 
overcomes the limitations of the methods that 
rely on peptide mass fingerprinting (PMF) 
databases. This can be used for non-sequenced 
organisms, antibodies, posttranslational 
modification (PTM), and endogenous peptides 
(Bellows & Floudas, 2010). The results of the 
peptide molecular modelling will be used as 
























Figure 1.  The molecular structure of antiviral peptides: a. Magainin-1 (GIGKFLHSAGKFGKAFVGEIMKS); b. 
Magainin-2 (GIGKFLHSAKKFGKAFVGEIMNS) 
 
Peptide-Binding Sites in SARS-CoV-2 
Mpro Identification. Identification, 
evaluation, and exploration of the binding site 
area most responsible for the antiviral activity 
of the SARS-CoV-2 Mpro macromolecule were 
prepared using BIOVIA Discovery Studio 2016 
(BIOVIA, 2016). All amino acid residues found 
around natural inhibitors within a defined 
radius (between 2 to 4 Å) are prepared for the 
binding site between the surface of protein 
macromolecules and peptide molecules in 
protein-peptide docking simulations. 
Protein-Peptide Docking Simulations. 
PatchDock is used for protein-peptide docking 
simulations (Kaczor et al., 2013; Sathya & 
Rajeswari, 2016; Aruleba et al., 2018). All 
antiviral peptide molecules for these 
simulations are modeled, and polar hydrogen 
atoms are added using the de novo method. 
Protein-peptide complex types are selected by 
default RMSD 4.0 Å grouping. The 
representation of the Connolly point's surface 
from the molecule into different components, 
including convex, concave, and flat patch, is 
generated through the PatchDock algorithm. 
PatchDock is optimized, refined, overhauled, 
and re-selected the side chain interface from the 
top 10 candidate solutions. It also changes 
relative molecular orientation by limiting 
flexibility in the side chains of interacting 
surfaces and allowing the movement of small, 
rigid objects. Analysis of the results of protein-
peptide docking simulations was carried out 
using BIOVIA Discovery Studio 2016 
(BIOVIA, 2016). 
ACE-2 Receptor Macromolecule 
Preparation. The ACE-2 receptor 
(Angiotensin Converting Enzyme-2 Receptor) 
macromolecules were downloaded from the 
Protein Data Bank (http://www.rcsb.org/pdb) 
with PDB ID 2AJF (Li et al., 2005). This ACE-
2 receptor macromolecule is prepared by 
removing water molecules and natural 
inhibitors, adding polar hydrogen atoms, and 
calculating the Kollman charge. 
Protein-Protein Docking Simulations. 
PatchDock is used to simulate protein docking 
of both peptide-protein complexes resulting 
from the protein-peptide docking methods 
(Kaczor et al., 2013; Sathya & Rajeswari, 2016; 
Aruleba et al., 2018). The default RMSD 4.0 Å 
grouping is used, and the protein-protein 
complex type is selected. The representation of 
the Connolly dot surface of the molecule into 
different components such as convex, concave, 
and flat patch is generated through the 
PatchDock algorithm. PatchDock is optimized, 
refined, overhauled, and reselected the side 
chain interface from the top 10 candidate 
solutions. It also changes the orientation of the 
molecule relative by limiting flexibility in the 
side chains of the interacting surface and 
allowing the movement of small, rigid objects. 
The system's suitability is verified by 
visualization observations using BIOVIA 
Discovery Studio 2016 (BIOVIA, 2016). 
 
RESULT AND DISCUSSION 
Protein-Peptide Docking Simulations. 
All antiviral peptides derived from frog skin 
(Xenopus laevis) have been proven to have 
affinity and interaction with the main protease 
(Mpro) of SARS-CoV-2, which acts as a target 
macromolecule using the protein-peptide 
a b 
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docking methods. The docking simulation 
results in Table 1 show that Magainin-2 has the 
best affinity with the active site SARS-CoV-2 
Mpro compared to Magainin-1 and natural 
inhibitors, with binding free energy values of 
−3054.53 kJ/mol, −201.46 kJ/mol, and 
−1171.44 kJ/mol, respectively. This 
phenomenon shows a promising sign that 
Magainin-2 has strong and stable bonds and 
interactions in the active site area of the SARS-
CoV-2 Mpro macromolecule. After that, all the 
complex results of protein-peptide docking 
simulations were selected for further studies 
using protein-protein docking simulations 
against ACE-2 receptors (Angiotensin 
Converting Enzyme-2 Receptor).
 
Table 1. Binding free energy between the peptide molecule and the SARS-CoV-2 Mpro macromolecule 
Peptide Molecule Binding Free Energy (kJ/mol) 
Natural inhibitor −1171.44 kJ/mol 
Magainin-1 −201.46 kJ/mol 
Magainin-2 −3054.53 kJ/mol 
 
The peptide molecules Magainin-1 and 
Magainin-2 show binding positions adjacent to 
natural inhibitors, and these three molecules 
can interact in polar patches of SARS-CoV-2 
Mpro macromolecules (Figure 2). However, 
natural inhibitors and the Magainin-1 peptide 
molecule can only interact with some amino 
acid residues found in the active sites of the 
SARS-CoV-2 Mpro macromolecules. Natural 
inhibitors can only form 5 interactions, 
consisting of 3 hydrogen bonds (with Met49, 
Asn142, and Gln189) and 2 hydrophobic 
interactions (with His41 and Met 165). Then the 
Magainin-1 peptide molecule can only form 6 
interactions, which include 5 hydrogen bonds 
(with Arg4, Lys5, Lys137, Ser139, and 

















Figure 2.  The conformation of natural inhibitor (yellow), Magainin-1 (green), and Magainin-2 (red) molecules in the 
SARS-CoV-2 Mpro macromolecular binding site 
 
Interestingly, the Magainin-2 peptide 
molecule has more interaction with the active 
site area of the Mpro SARS-CoV-2 
macromolecule than the natural inhibitor and 
Magainin-1 peptide molecule. These peptide 
molecules are capable of forming 13 
interactions, including 6 hydrogen bonds (with 
Thr24, Thr25, His41, Met49, Cys145, and 
Gln192), 1 electrostatic interaction (with 
Glu166), and 6 hydrophobic interactions (with 
Met165, Leu167, Pro168, Ala191, Ala193, and 
Ala194) (Table 2). Also, the binding position 
between the Magainin-2 peptide molecule and 
natural inhibitors has similarities. This 
phenomenon is proven by forming bonds with 
several amino acid residues such as His41, 
Met49, and Met165.
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Table 2. Profiles of amino acid residues from SARS-CoV-2 Mpro macromolecules that interact with peptide molecules 
Peptide Molecule Amino Acid Residues 
Natural inhibitor His41***, Met49*, Asn142*, Met165***, Gln189* 
Magainin-1 Arg4*, Lys5*, Lys137*, Ser139*, Phe140*, Ser284**  
Magainin-2 
Thr24*, Thr25*, His41*, Met49*, Cys145*, Met165***, 
Glu166**, Leu167***, Pro168***, Ala191***, 
Gln192*, Ala193***, Ala194*** 
Notes: *= hydrogen bond; **= electrostatic interaction; ***= hydrophobic interaction 
 
These interactions can be formed due to 
hydrogen bonds, especially peptide molecules, 
which act as hydrogen bond donors and protein 
amino acid residues as hydrogen bond 
acceptors. Most hydrogen bonds between 
protein macromolecules and peptide molecules 
are relatively strong, with average bond lengths 
ranging from 3 Å. In addition to hydrogen 
bonds, interactions between peptide molecules 
and SARS-CoV-2 Mpro are also dominated by 
hydrophobic interactions. So it can be predicted 
that hydrogen bonds and hydrophobic 
interactions that contribute to protein 
macromolecules are responsible for stabilizing 
protein-peptide complexes. 
Protein-Protein Docking Simulations. 
Furthermore, identification, evaluation, and 
exploration using the protein-protein docking 
methods after the protein macromolecule 
complex and peptide molecules are formed in 
the previous stage. The purpose of this docking 
simulations is to observe the effect of each 
protein-peptide complex in preventing the 
attachment of SARS-CoV-2 Mpro 
macromolecules to the surface area of the ACE-
2 receptor. Best affinity with strong and stable 
interaction of peptide molecules against SARS-
CoV-2 Mpro macromolecules is predicted to 
inhibit the entry of coronavirus into cells and 
host tissues due to the inability of coronavirus 
to reach ACE-2 receptors in the signaling 
process of viral infection. It is also important to 
explore amino acid residues that play an 
important role in resisting the formation of 
molecular interactions between the SARS-
CoV-2 Mpro macromolecular binding site and 
the surface of the ACE-2 receptor.
 
Table 3. The atomic contact energy (ACE) score of each protein-peptide complex against the ACE-2 receptor 
Protein-Peptide Complex Atomic Contact Energy (kJ/mol) 
Natural inhibitor + SARS-CoV-2 Mpro −204.26 kJ/mol 
Magainin-1 + SARS-CoV-2 Mpro 231.75 kJ/mol 
Magainin-2 + SARS-CoV-2 Mpro 1697.99 kJ/mol 
 
Protein-protein docking simulations results 
in Table 3 show that the Magainin-1 and 
Magainin-2 protein-peptide complex have 
positive ACE scores, with values of 231.75 
kJ/mol and 1697.99 kJ/mol, respectively. In 
contrast, natural inhibitors have a negative ACE 
score, with a value of −204.26 kJ/mol. This 
phenomenon proves that the ability of the two 
Magainin peptide molecules to inhibit the 
attachment of ACE-2 receptors is better than 
natural inhibitors.
 
Table 4. Amino acid residues from ACE-2 receptor that play a role in the formation of unfavorable interactions 
Protein-Peptide Complex Amino Acid Residues 
Natural inhibitor + SARS-CoV-2 Mpro Arg115, Lys131, Cys133, Gln139 
Magainin-1 + SARS-CoV-2 Mpro Gly319, Ala387, Arg559  
Magainin-2 + SARS-CoV-2 Mpro 
Lys313, Val316, Ser317, Ala387, Pro426, Asp427, 
Asn546, Thr548, Gln552, Phe555, Asn556 
 
Moreover, the molecular structure of 
Magainin-2 is capable of forming many 
unfavorable interactions on the surface of the 
ACE-2 receptor. Several amino acid residues 
that form unfavorable interactions include 
Lys313, Val316, Ser317, Ala387, Pro426, 
Asp427, Asn546, Thr548, Gln552, Phe555, and 
Asn556 (Table 4). This interaction is predicted 
Vol 8(1), June 2020                                                                                                          Biogenesis 109 
 
to be responsible for preventing the formation 
of infection signals in SARS-COV-2 (Cheng et 
al., 2016; Wheeler et al., 2016). 
 
CONCLUSION 
Peptide molecules Magainin-1 and 
Magainin-2 can bind strongly and stably to the 
binding site area of the SARS-CoV-2 Mpro 
macromolecule. Interestingly, Magainin-2 has 
the best affinity and interaction with the SARS-
CoV-2 Mpro macromolecule's active site, with 
a binding free energy value of −3054.53 kJ/mol. 
The Magainin-2 peptide molecule can also 
inhibit the formation of interactions with the 
ACE-2 receptor surface because it has a 
positive ACE score, with a value of 1697.99 
kJ/mol. Therefore, the results of this research 
indicate that the peptide molecules Magainin-1 
and Magainin-2 have the potential to be further 
developed as natural candidate inhibitors of the 
SARS-CoV-2 Mpro macromolecules in the 
treatment of infectious diseases of COVID-19. 
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